PF-00835231
CAS No. 870153-29-0
PF-00835231 ( —— )
产品货号. M28699 CAS No. 870153-29-0
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1126 | 有现货 |
|
10MG | ¥1847 | 有现货 |
|
25MG | ¥3718 | 有现货 |
|
50MG | ¥5565 | 有现货 |
|
100MG | ¥7930 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称PF-00835231
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
产品描述PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体glucocerebrosidase
-
研究领域——
-
适应症——
化学信息
-
CAS Number870153-29-0
-
分子量944.1
-
分子式C48H63N8O12
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC(C)C[C@@H](C(N[C@@H](C[C@H](CCN1)C1=O)C(CO)=O)=O)NC(c1cc(c(OC)ccc2)c2[nH]1)=OCC(C)C[C@@H](C(N[C@@H](C[C@H](CCN1)C1=O)C(CO)=O)=O)NC(c1cc(c(OC)ccc2)c2[nH]1)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Rogers S, et al. Discovery, SAR, and Biological Evaluation of Non-inhibitory Chaperones of Glucocerebrosidase. 2012 Mar 27 [updated 2013 Mar 7].
产品手册
关联产品
-
9-Phenylcarbazole
9-Phenylcarbazole is a useful organic compound for research related to life sciences.
-
Arjunglucoside I
Arjunglucoside I has anti-inflammatory activity, it exhibits significant activity against carrageenan-induced paw edema in rat.
-
Fmoc-PEG12-NHS ester
Fmoc-PEG12-NHS ester is a PEG-based PROTAC linker that can be used to synthesize PROTACs.